title: BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis.
abstract: OBJECTIVE
  To assess the impact of BRCA1/2 test results on carriers' reproductive decision-making and the factors determining their theoretical intentions about preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND).
  
  
  METHODS
  Unaffected BRCA1/2 mutation carriers of childbearing age (N = 605; 449 women; 151 men) were included at least 1 year after the disclosure of their test results in a cross-sectional survey nested in a national cohort. Multivariate adjustment was performed on the data obtained in self-administered questionnaires.
  
  
  RESULTS
  Response rate was 81.0%. Overall, 32.5% and 50% said that they would undergo PGD/PND, respectively, at a theoretical next pregnancy, whereas only 12.1% found termination of pregnancy (TOP) acceptable. Theoretical intentions toward PGD did not depend on gender/age, but were higher among those with no future childbearing plans (adjusted odds ratio (AOR) 95% confidence interval (CI): 3.5 (1.9-6.4)) and those having fewer relatives with cancer (AOR 1.5 95% CI (1.0-2.3)). Greater TOP acceptability was observed among males and those with lower educational levels; 85.4% of respondents agreed that information about PGD/PND should be systematically delivered with the test results.
  
  
  CONCLUSIONS
  The closer to reproductive decision-making BRCA1/2 carriers are, i.e., when they are more likely to be making future reproductive plans, the less frequently they intend to have PGD. Carriers' theoretical intentions toward PND are discussed further.
authors.affiliation: INSERM, U912, Marseille, France. claire.julian-reynier@inserm.fr
authors.forename: Claire
authors.initials: C
authors.lastname: Julian-Reynier
authors.forename: Roxane
authors.initials: R
authors.lastname: Fabre
authors.forename: Isabelle
authors.initials: I
authors.lastname: Coupier
authors.forename: Dominique
authors.initials: D
authors.lastname: Stoppa-Lyonnet
authors.forename: Christine
authors.initials: C
authors.lastname: Lasset
authors.forename: Olivier
authors.initials: O
authors.lastname: Caron
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Mouret-Fourme
authors.forename: Pascaline
authors.initials: P
authors.lastname: Berthet
authors.forename: Laurence
authors.initials: L
authors.lastname: Faivre
authors.forename: Marc
authors.initials: M
authors.lastname: Frenay
authors.forename: Paul
authors.initials: P
authors.lastname: Gesta
authors.forename: Laurence
authors.initials: L
authors.lastname: Gladieff
authors.forename: Anne-Deborah
authors.initials: AD
authors.lastname: Bouhnik
authors.forename: Christel
authors.initials: C
authors.lastname: Protière
authors.forename: Catherine
authors.initials: C
authors.lastname: Noguès
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics*; D015331:Cohort Studies; D003657:Decision Making; D005260:Female; D005602:France; D020022:Genetic Predisposition to Disease / Q000523:psychology; D005820:Genetic Testing; D006301:Health Services Needs and Demand; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D019836:Preimplantation Diagnosis / Q000639:trends*; D011296:Prenatal Diagnosis / Q000639:trends*; D011795:Surveys and Questionnaires
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human